ScreenerHero
SONASona Nanotech Inc.
CNQ · CA · Healthcare · Biotechnology · sonanano.com
0.3150CADMkt Cap: 23.32M $P/E: —

Sona Nanotech Inc. operates as a nanotechnology life sciences company in the United States and Canada The company researchers and develops gold nanoparticles for potential therapies, including photothermal therapy, tumor…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
ARGENX SE
$60.19BUSDP/E 39.1
UCB
UCB SA
$45.16BUSDP/E 19.2
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.17BUSDP/E 26.2
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5
HeadlineSourceTime
Older
Sona Nanotech appoints two oncologists to scientific advisory board

Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has announced the appointment of two oncologists, Michael Smylie and Jonathan Trites, to its scientific advisory board to support its ongoing clinical and research initiatives. Dr Smylie is a medical oncologist at the Cross Cancer Institute in...

Proactive
Sona Nanotech preclinical study shows tumor regression in colorectal cancer model

Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) revealed promising new study results indicating that its Targeted Hyperthermia Therapy (THT) in combination with immunotherapy cleared tumors in 38% of animals in a preclinical colon cancer study, signaling potential for cancers that typically resist...

Proactive
Why precision oncology may be poised for a reset: a conversation with Sona Nanotech

Cancer has quietly become the pharmaceutical industry’s most lucrative disease area. In 2024 alone, global cancer drug sales exceeded $200 billion, making oncology the single largest revenue category in biopharma, well ahead of even the fast-growing obesity drug market. Yet behind the...

Proactive